Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of adenylyl cyclase activity and expression by a sigma1 receptor ligand and putative atypical antipsychotic.

X Monroy1, G Romero, M P Pérez

  • 1Department of Neuropharmacology, Research Center, Laboratoris Esteve, S.A., Verge de Montserrat 221, 08041-Barcelona, Spain.

Neuroreport
|July 4, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visual evoked potentials and development on children with congenital cataract with surgery after 4 months of age.

Archivos de la Sociedad Espanola de Oftalmologia·2025
Same author

Amlodipine use during pregnancy: Current status in the medical care field in Argentina.

Hipertension y riesgo vascular·2025
Same author

Statins and preeclampsia: An update from the Working Group on Hypertension in Women, Argentine Society of Hypertension.

Hipertension y riesgo vascular·2025
Same author

From micro to mesoscale: Understanding the influence of macroalgal communities on Ostreopsis Schmidt blooms.

Harmful algae·2024
Same author

Factors affecting N-acetyl-β-D-glucosaminidase as an indicator for mastitis detection in dairy sheep.

Animal : an international journal of animal bioscience·2024
Same author

In vitro models for neuropathic pain phenotypic screening in brain therapeutics.

Pharmacological research·2024

Chronic treatment with E-5842, a sigma1 receptor ligand, decreased adenylyl cyclase type I in rat frontal cortex. This finding may inform the use of this atypical antipsychotic in psychiatric patients.

Area of Science:

  • Neuropharmacology
  • Molecular Psychiatry

Background:

  • Atypical antipsychotics modulate neurotransmitter systems.
  • Sigma1 receptor ligands are investigated for psychiatric disorders.

Purpose of the Study:

  • To investigate the effect of E-5842, a sigma1 receptor ligand and potential atypical antipsychotic, on the adenylyl cyclase system.
  • To determine if E-5842 induces changes in adenylyl cyclase (AC) activity and immunoreactivity.

Main Methods:

  • Rats received acute (2 h) or repeated (21 days) administration of E-5842.
  • Adenylyl cyclase type I immunoreactivity and activity were measured in rat brain membranes (frontal cortex, hippocampus, striatum).

Main Results:

  • Repeated E-5842 treatment significantly decreased adenylyl cyclase type I immunoreactivity and activity in the rat frontal cortex.

Related Experiment Videos

  • Acute treatment with E-5842 did not affect adenylyl cyclase type I.
  • No significant changes were observed in other brain regions or for adenylyl cyclase types V/VI.

    • Conclusions:

    • Chronic administration of E-5842 selectively alters adenylyl cyclase type I in the frontal cortex.
    • These changes, occurring after prolonged treatment, may be relevant to the mechanism of action of sigma receptor ligands and atypical antipsychotics.
    • Findings suggest potential implications for long-term psychiatric treatment strategies.